Natural killer (NK) cells play a crucial role in the immune system and can recognize and kill cancer cells. Research in this area is focused on strategies for enhancing NK cell activity in tumor immunotherapy. These strategies include using monoclonal and multi-specific antibodies, as well as immune modulator molecules like cytokines, to redirect and stimulate …Read More >

Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where cytotoxic payloads released by antibodies diffuse and kill nearby tumor cells, is a crucial mechanism, particularly in heterogeneous tumors where not all cells express the target antigen. This effect can enhance ADC efficacy, especially when …Read More >

Cancers, like cervical cancer and head & neck cancer, are strongly linked to human papillomavirus (HPV) infection. Targeting the HPV virus, particularly through vaccines, is a promising approach for treating HPV-related cancers. Vaccines can be designed to stimulate the immune system to target and eliminate HPV-infected cells, potentially preventing cancer progression or even treating established …Read More >

From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the largest and longest-standing cancer research conferences in the world, will be held in Chicago. At this year’s AACR meeting, WuXi Biology has been selected to present several posters detailing latest scientific insights, covering a range …Read More >

At this year’s annual meeting of the American Association for Cancer Research (AACR), WuXi Biology has been selected to present multiple posters detailing latest scientific insights, covering a range of cutting-edge topics from preclinical tumor model development and biomarker discovery, to the evaluation of novel anti-cancer therapies. Explore this quick overview of WuXi Biology’s pioneering …Read More >

Synthetic lethality, where combining two non-lethal mutations results in cell death, is exploited in cancer therapy, with PARP inhibitors like olaparib targeting BRCA-deficient cells by exploiting this interaction.  Werner syndrome helicase (WRN) is a synthetic lethal target in cancers with microsatellite instability due to impaired DNA mismatch repair.  WRN is synthetically lethal with MLH1, a …Read More >

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The development of targeted therapies for overcoming paclitaxel resistance represents an unmet medical need. Although not fully understood, the mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce …Read More >

Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a combination therapy regimen for DLBCL that combines chemotherapy drugs with rituximab). Polatuzumab vedotin is an antibody-drug conjugate (ADC) used to treat DLBCL, both in first-line treatment and for relapsed or refractory cases. At the 2025 …Read More >

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed.  The successful development of next generation ADCs necessitates the establishment of tumor models that address the mechanism of action underlying this resistance. At the 2025 World …Read More >